Relative to the prescription drug affordability board.
Note
Overall, the passage of SB 450 signifies a critical step towards addressing prescription drug affordability and regulatory oversight, although it also underscores the ongoing challenges of balancing consumer protection with the operational realities of the pharmaceutical industry.
Impact
The bill's amendments are designed to foster a more transparent framework regarding the pricing of prescription drugs, aiming to promote affordability for consumers while ensuring fair practices among pharmaceutical companies. By defining the roles and powers of the board more clearly, SB 450 strengthens its capacity to assess fees and manage a dedicated fund for administrative purposes, which can directly impact how prescription medications are priced and managed within New Hampshire.
Summary
Senate Bill 450 aims to enhance the governance and operational efficiency of the New Hampshire Prescription Drug Affordability Board. Key amendments include clarifying the definitions of 'manufacturer' and 'pricing unit' to ensure that the board effectively determines price assessments and maintains oversight on prescription drug pricing within the state. The bill proposes structural changes that allow for additional alternate board members to participate in decision-making processes, thereby increasing its adaptability and responsiveness to various situations.
Contention
Some points of contention surrounding SB 450 include concerns from various stakeholders about the balance of power within the board and its potential implications for pharmaceutical companies and consumers. While the bill grants the board expanded authority to charge fees and manage funds, there may be apprehensions regarding how these financial assessments will be perceived by the industry, particularly by smaller manufacturers who could be disproportionately affected. Additionally, the criminal penalties for breaches of confidentiality have sparked discussions regarding the implications of enforcing such measures and protecting sensitive information.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.